Related Experiment Video
Updated: Dec 21, 2025
08:13
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
4.9K
Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα
AbdelAziz R Jalil1,2, Jason C Andrechak2,3, Dennis E Discher2,3
1Department of Chemistry, University of Pennsylvania, Philadelphia, PA, USA.
Antibody Therapeutics
|May 19, 2020
Summary
The CD47-SIRPα macrophage checkpoint interaction is a cancer therapy target. Combination therapies, particularly anti-CD47 with rituximab, show promise against lymphomas.
Area of Science:
- Immunology
- Cancer Biology
- Drug Development
Background:
- The CD47-SIRPα axis is an anti-phagocytic checkpoint involving macrophages and various cell types, including cancer cells.
- Antibodies targeting CD47 or SIRPα are in development as cancer therapeutics.
Purpose of the Study:
- To review clinical trials and preclinical data on CD47 blockade in cancer therapy.
- To examine the interaction and structural features of CD47-SIRPα.
Main Methods:
- Review of preclinical and clinical trial data.
- Analysis of CD47-SIRPα interaction and structural characteristics.
Main Results:
- CD47 blockade as monotherapy shows limited efficacy in human trials, except for specific lymphomas.
- Preclinical studies in mouse models suggest efficacy, but these models may be less representative of human tumors.
- Combination therapy of anti-CD47 with rituximab demonstrates efficacy in human lymphoma trials.
Conclusions:
- The CD47-SIRPα checkpoint is a viable target, especially in combination therapies.
- Combination strategies, like anti-CD47 with rituximab, hold significant promise for treating hematological malignancies such as lymphoma.
